Capricor's biologics license application for deramiocel (CAP-1002) is draws largely on the Phase 2 HOPE-2 trial and its ...

Deramiocel is a cell therapy that has healing effects in muscle cells. If approved, deramiocel would be a once-quarterly ...

Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...

Shares of Capricor Therapeutics CAPR gained 8.4% on Thursday following the completion of the submission of a biologics ...

"The submission of the BLA marks a pivotal step for Capricor and those impacted by DMD. This BLA is the culmination of a body of work that has been focused on bringing this potentially ...

US biotech Capricor Therapeutics today announced the completion of the submission of its Biologics License Application (BLA) ...

Capricor Therapeutics seeks US FDA approval for deramiocel for the treatment of Duchenne muscular dystrophy: San Diego Saturday, January 4, 2025, 15:00 Hrs [IST] Capricor Therapeu ...

Shares of Capricor Therapeutics ($CAPR) were up 8.41% up on Thursday after the rare diseases-focused biotech said it ...

The Orphan Drug designation provides Capricor with several benefits that support the development of deramiocel in Europe, including market exclusivity for 10 years if approval is granted and ...

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology firm specializing in innovative cell and exosome-based therapies for rare diseases, finalized the submission of its Biologics License ...

Capricor Therapeutics (CAPR) announced the completion of the submission of its Biologics License Application, BLA, to the U.S. Food and Drug ...

"We believe that the strength of this application is that deramiocel has shown in multiple clinical trials attenuation of the cardiac implications of DMD. We look forward to working with the FDA ...